deprexis is clinically shown to significantly reduce depressive symptoms1
EU and Switzerland: deprexis is intended to provide therapeutic methods and exercises based on evidence-based psychological and psychotherapeutic therapies for patients with unipolar depression or depressive disorders, to help them managing their depression or depressive disorder. deprexis is intended as a self-application supplemental to care-as-usual for patients 18 years of age or older. deprexis can be used for a period of 90 days. deprexis is neither intended to replace treatment provided by a health care provider nor to provide information which is used to take decisions with diagnosis or therapeutic purposes.
USA: deprexis is web application indicated for the adjunctive treatment of chronic or recurrent depression or depressive disorders as a primary or secondary diagnosis (e.g. as a comorbidity in multiple sclerosis or epilepsy) for patients 18 years of age or older who are experiencing a depressive episode.
Vertretungsberechtigter Vorstand: Dr. Mario Weiss (Vorsitzender)
Registergericht: Amtsgericht Hamburg
Registernr.: HRB 82741
deprexis ist ein CE-gekennzeichnetes Medizinprodukt